Faozia Pio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faozia Pio has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andeulazia Murdock
Department of Urology, George Washington University School of Medicine, 2300 I St NW, Washington, DC 20052, USA
3 shared publications - Michael J. Whalen
Department of Urology, School of Medicine, George Washington University, Washington, DC
3 shared publications Lekhaj Daggubati
Department of Neurological Surgery George Washington University School of Medicine & Health Sciences Washington DC USA
2 shared publicationsMalik Obeidallah
Department of Neurological Surgery George Washington University School of Medicine & Health Sciences Washington DC USA
2 shared publicationsMeagan Mitchell
Department of Neurological Surgery George Washington University School of Medicine & Health Sciences Washington DC USA
2 shared publications- Renee E. Fuller
Department of Urology, George Washington University School of Medicine, 2300 I St NW, Washington, DC 20052, USA
2 shared publications
Latest Publications
- Open Access
- 14 June 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72942
Surgical Resection of Metastatic Male Breast Cancer to the Brain: An Illustrative Case Report
Male breast cancer is rare, accounting for less than 1% of all breast cancers, and central nervous system (CNS) metastases are an uncommon but poor prognostic manifestation. The aim of the current case report is to discuss a 50‐year‐old man with stage IV estrogen receptor–positive, progesterone receptor–positive, and HER2‐positive breast cancer who presented with new‐onset focal neurological deficits and was found to have a solitary left parietal brain metastasis with vasogenic edema and midline shift. He underwent gross total resection via craniotomy, with pathology confirming metastatic ductal carcinoma consistent with the primary tumor. Postoperatively, he received adjuvant stereotactic radiosurgery (30–35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T‐DXd) for improved CNS‐directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS‐penetrant HER2‐targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.
- 14 June 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72942
Open AccessSurgical Resection of Metastatic Male Breast Cancer to the Brain: An Illustrative Case Report
Male breast cancer is rare, accounting for less than 1% of all breast cancers, and central nervous system (CNS) metastases are an uncommon but poor prognostic manifestation. The aim of the current case report is to discuss a 50‐year‐old man with stage IV estrogen receptor–positive, progesterone receptor–positive, and HER2‐positive breast cancer who presented with new‐onset focal neurological deficits and was found to have a solitary left parietal brain metastasis with vasogenic edema and midline shift. He underwent gross total resection via craniotomy, with pathology confirming metastatic ductal carcinoma consistent with the primary tumor. Postoperatively, he received adjuvant stereotactic radiosurgery (30–35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T‐DXd) for improved CNS‐directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS‐penetrant HER2‐targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.
- Open Access
- 3 November 2025
- Published by Wiley
Surgical Resection of Metastatic Male Breast Cancer to the Brain: An Illustrative Case Report
- 3 November 2025
- Published by Wiley
Open AccessSurgical Resection of Metastatic Male Breast Cancer to the Brain: An Illustrative Case Report
- Open Access
- 6 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6909-6937
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.
- 6 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6909-6937
Open AccessThe Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.
- Open Access
The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer
Prostate cancer is the most common non-cutaneous malignancy in men, with the majority of newly diagnosed patients eligible for active surveillance. Despite definitive treatment, a considerable percentage of men will experience biochemical recurrence and even regional and distant metastatic recurrence after radiation therapy or radical prostatectomy. Salvage prostatectomy, while oncologically effective, poses significant morbidity with poor functional outcomes. Salvage cryotherapy has emerged as a promising alternative for localized recurrence, demonstrating safety and efficacy. This review examines the oncologic and functional outcomes of whole-gland and focal salvage cryotherapy, including disease-free survival, cancer-specific survival, and overall survival. The crucial role of multiparametric prostate MRI and evolving role of next-generation PSMA-targeted PET imaging are also examined. The comparison of outcomes of cryotherapy to other salvage ablation modalities, such as high-intensity focused ultrasound (HIFU), is also explored.
Open AccessThe Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer
Prostate cancer is the most common non-cutaneous malignancy in men, with the majority of newly diagnosed patients eligible for active surveillance. Despite definitive treatment, a considerable percentage of men will experience biochemical recurrence and even regional and distant metastatic recurrence after radiation therapy or radical prostatectomy. Salvage prostatectomy, while oncologically effective, poses significant morbidity with poor functional outcomes. Salvage cryotherapy has emerged as a promising alternative for localized recurrence, demonstrating safety and efficacy. This review examines the oncologic and functional outcomes of whole-gland and focal salvage cryotherapy, including disease-free survival, cancer-specific survival, and overall survival. The crucial role of multiparametric prostate MRI and evolving role of next-generation PSMA-targeted PET imaging are also examined. The comparison of outcomes of cryotherapy to other salvage ablation modalities, such as high-intensity focused ultrasound (HIFU), is also explored.
- Open Access
- 17 June 2024
- Published by MDPI AG in Preprints.org
The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer
Prostate cancer is the most common non-cutaneous malignancy in men, with the majority of newly diagnosed patients eligible for active surveillance. Despite definitive treatment, a considerable percentage of men will experience biochemical recurrence and even regional and distant metastatic recurrence after radiation therapy or radical prostatectomy. Salvage prostatectomy, while oncologically effective, poses significant morbidity with poor functional outcomes. Salvage cryotherapy has emerged as a promising alternative for localized recurrence, demonstrating safety and efficacy. This review examines the oncologic and functional outcomes of whole-gland and focal salvage cryotherapy, including disease-free survival, cancer-specific survival, and overall survival. The crucial role of multiparametric prostate MRI and evolving role of next-generation PSMA-targeted PET imaging is also examined. Comparison of outcomes of cryotherapy to other salvage ablation modalities, such as high-intensity focused ultrasound (HIFU) is also explored.
- 17 June 2024
- Published by MDPI AG in Preprints.org
Open AccessThe Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer
Prostate cancer is the most common non-cutaneous malignancy in men, with the majority of newly diagnosed patients eligible for active surveillance. Despite definitive treatment, a considerable percentage of men will experience biochemical recurrence and even regional and distant metastatic recurrence after radiation therapy or radical prostatectomy. Salvage prostatectomy, while oncologically effective, poses significant morbidity with poor functional outcomes. Salvage cryotherapy has emerged as a promising alternative for localized recurrence, demonstrating safety and efficacy. This review examines the oncologic and functional outcomes of whole-gland and focal salvage cryotherapy, including disease-free survival, cancer-specific survival, and overall survival. The crucial role of multiparametric prostate MRI and evolving role of next-generation PSMA-targeted PET imaging is also examined. Comparison of outcomes of cryotherapy to other salvage ablation modalities, such as high-intensity focused ultrasound (HIFU) is also explored.